Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas
NCT07082803Phase 1Recruiting
- Sponsor
- Treeline Biosciences
- Start
- Jun 2025
- Primary completion
- Sep 2030
- Countries
- 3
01
Overview
Phase 1, open-label trial of TLN-121 in non-Hodgkin lymphoma (NHL) (2 arms), sponsored by Treeline Biosciences. Primary endpoints: Dose-Limiting Toxicity at 2 years, Treatment-Emergent and Treatment-Related Adverse Events at 2 years and 2 more. Started Jun 2025; status: recruiting.
02
Drugs
TLN-121
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT07082803.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07082803.